Boehringer's Gilotrif Gets FDA Approval for NSCLC

Boehringer Ingelheim announces approval of its first oncology drug after regulators in the USA gave the green light to Gilotrif for late-stage non-small cell lung cancer. Read the full story

More News:

All news »

What are your comments?

Join the discussion today. Login Here.


No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments